3-(5-chlorofuran-2-yl)-5-hydroxy-4-phenyl-4,5-dihydroisoxazole-5-carboxylic acid | 1171190-83-2

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 芳基卤化物
• 英文名称: 3-(5-chlorofuran-2-yl)-5-hydroxy-4-phenyl-4,5-dihydroisoxazole-5-carboxylic acid
• 英文别名: [3-(5-chlorofuran-2-yl)-4-phenyl-5-hydroxy-2-isoxazolin-5-yl]carboxylic acid；3-(5-chlorofuran-2-yl)-5-hydroxy-4-phenyl-4H-1,2-oxazole-5-carboxylic acid
• CAS: 1171190-83-2
• 化学式: C₁₄H₁₀ClNO₅
• 分子量: 307.69
• InChiKey: GSHKCDRVDFLSEO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  92.3
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  3-(5-chlorofuran-2-yl)-5-hydroxy-4-phenyl-4,5-dihydroisoxazole-5-carboxylic acid 在 甲醇 、 硫酸 、 三氟化硼 、 水 、 sodium carbonate 作用下， 反应 11.08h， 生成 methyl [3-(5-chlorofuran-2-yl)-4-phenylisoxazol-5-yl]carboxylate
  参考文献：
  名称：

  Functionalized diarylisoxazoles inhibitors of ciclooxygenase

  摘要：

  本发明涉及异恶唑衍生物，特别是二芳基异恶唑衍生物，用作环氧合酶（COX）的抑制剂，特别是环氧合酶-1（COX-1）的抑制剂，以及它们的药物组合物、其制备方法以及用于化学预防和治疗炎症综合征以及预防和治疗癌症，特别是肠癌、卵巢癌和皮肤癌，在疼痛综合征的治疗中，特别是手术后，以及在心血管领域作为抗血栓/血管保护剂/心脏保护剂的用途。

  公开号：

  US20090181970A1
• 作为产物：
  描述：

  苯丙酮酸 、 5-chlorofuran-2-carbonitrileoxide 在 正丁基锂 、 二异丙胺 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 17.0h， 以188 mg的产率得到3-(5-chlorofuran-2-yl)-5-hydroxy-4-phenyl-4,5-dihydroisoxazole-5-carboxylic acid
  参考文献：
  名称：

  Synthesis, Pharmacological Characterization, and Docking Analysis of a Novel Family of Diarylisoxazoles as Highly Selective Cyclooxygenase-1 (COX-1) Inhibitors

  摘要：

  3-(5-Chlorofuran-2-yl)-5-methyl-4-phenylisoxazole (P6), a known selective cyclooxygenase-1 (COX-1) inhibitor, was used to design a new series of 3,4-diarylisoxazoles in order to improve its biochemical COX-1 selectivity and antiplatelet efficacy. Structure activity relationships were studied using human whole blood assays for COX-1 and COX-2 inhibition in vitro, and results showed that the simultaneous presence of S-methyl (or -CF3), 4-phenyl, and 5-chloro(-bromo or -methyl)furan-2-yl groups on the isoxazole core was essential for their selectivity toward COX-1. 3g, 3s, 3d were potent and selective COX-1 inhibitors that affected platelet aggregation in vitro through the inhibition of COX-1-dependent thromboxane (TX) A(2). Moreover, we characterized their kinetics of COX-1 inhibition. 3g, 3s, and 3d were more potent inhibitors of platelet COX-1 and aggregation than P6 (named 6) for their tighter binding to the enzyme. The pharmacological results were supported by docking simulations. The oral administration of 3d to mice translated into preferential inhibition of platelet-derived TXA(2) over protective vascular-derived prostac-yclin (PGI(2)).

  DOI：

  10.1021/jm301905a

文献信息

• Functionalized diarylisoxazoles inhibitors of ciclooxygenase
  申请人：Scilimati Antonio

  公开号：US20090181970A1

  公开（公告）日：2009-07-16

  The present invention refers to isoxazole derivatives, in particular diarylisoxazole derivatives inhibitors of cyclooxygenase (COX), in particular cyclooxygenase-1 (COX-1), to their pharmaceutical compositions, the process for their preparation and their use for the chemoprevention and treatment of inflammatory syndromes and in the prevention and treatment of carcinomas, in particular intestinal, ovarian and cutaneous carcinomas, in the treatment of pain syndromes, in particular after surgery, and in the cardiovascular field as antithrombotics/vasoprotectives/cardioprotectives.

  本发明涉及异恶唑衍生物，特别是二芳基异恶唑衍生物，用作环氧合酶（COX）的抑制剂，特别是环氧合酶-1（COX-1）的抑制剂，以及它们的药物组合物、其制备方法以及用于化学预防和治疗炎症综合征以及预防和治疗癌症，特别是肠癌、卵巢癌和皮肤癌，在疼痛综合征的治疗中，特别是手术后，以及在心血管领域作为抗血栓/血管保护剂/心脏保护剂的用途。
• US7989450B2
  申请人：——

  公开号：US7989450B2

  公开（公告）日：2011-08-02
• Synthesis, Pharmacological Characterization, and Docking Analysis of a Novel Family of Diarylisoxazoles as Highly Selective Cyclooxygenase-1 (COX-1) Inhibitors
  作者：Paola Vitale、Stefania Tacconelli、Maria Grazia Perrone、Paola Malerba、Laura Simone、Antonio Scilimati、Antonio Lavecchia、Melania Dovizio、Emanuela Marcantoni、Annalisa Bruno、Paola Patrignani

  DOI：10.1021/jm301905a

  日期：2013.6.13

  3-(5-Chlorofuran-2-yl)-5-methyl-4-phenylisoxazole (P6), a known selective cyclooxygenase-1 (COX-1) inhibitor, was used to design a new series of 3,4-diarylisoxazoles in order to improve its biochemical COX-1 selectivity and antiplatelet efficacy. Structure activity relationships were studied using human whole blood assays for COX-1 and COX-2 inhibition in vitro, and results showed that the simultaneous presence of S-methyl (or -CF3), 4-phenyl, and 5-chloro(-bromo or -methyl)furan-2-yl groups on the isoxazole core was essential for their selectivity toward COX-1. 3g, 3s, 3d were potent and selective COX-1 inhibitors that affected platelet aggregation in vitro through the inhibition of COX-1-dependent thromboxane (TX) A(2). Moreover, we characterized their kinetics of COX-1 inhibition. 3g, 3s, and 3d were more potent inhibitors of platelet COX-1 and aggregation than P6 (named 6) for their tighter binding to the enzyme. The pharmacological results were supported by docking simulations. The oral administration of 3d to mice translated into preferential inhibition of platelet-derived TXA(2) over protective vascular-derived prostac-yclin (PGI(2)).